((Rami Komrokji, MD))
Complete remission, or CR, refers to the reduction of myloblasts to under 5% with complete count recovery.
CR correlates with better outcomes. When assessing patients for transplant, doctors are looking for patients in CR rather than those with active disease.
In my experience, I administer consolidation with VYXEOS prior to hematopoietic stem cell transplant to help maintain remission while aspects of transplant, such as finding an available donor, are finalized.
With VYXEOS, up to 2 cycles of consolidation can be administered.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION